A detailed history of Rhumbline Advisers transactions in Oric Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 92,702 shares of ORIC stock, worth $987,276. This represents 0.0% of its overall portfolio holdings.

Number of Shares
92,702
Previous 60,300 53.73%
Holding current value
$987,276
Previous $829,000 20.99%
% of portfolio
0.0%
Previous 0.0%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 01, 2024

BUY
$6.63 - $12.93 $214,825 - $418,957
32,402 Added 53.73%
92,702 $655,000
Q1 2024

May 09, 2024

BUY
$8.04 - $16.03 $19,263 - $38,407
2,396 Added 4.14%
60,300 $829,000
Q4 2023

Feb 08, 2024

SELL
$5.41 - $9.43 $3,662 - $6,384
-677 Reduced 1.16%
57,904 $532,000
Q3 2023

Nov 09, 2023

BUY
$6.05 - $9.28 $40,389 - $61,953
6,676 Added 12.86%
58,581 $354,000
Q2 2023

Aug 08, 2023

BUY
$4.95 - $8.4 $256,929 - $436,002
51,905 New
51,905 $402,000
Q2 2022

Aug 11, 2022

SELL
$2.7 - $7.07 $104,951 - $274,817
-38,871 Closed
0 $0
Q1 2022

May 12, 2022

BUY
$4.54 - $16.1 $13,261 - $47,028
2,921 Added 8.13%
38,871 $208,000
Q4 2021

Feb 10, 2022

SELL
$12.01 - $20.3 $4,828 - $8,160
-402 Reduced 1.11%
35,950 $528,000
Q3 2021

Nov 12, 2021

BUY
$15.9 - $25.22 $40,990 - $65,017
2,578 Added 7.63%
36,352 $760,000
Q2 2021

Aug 05, 2021

BUY
$17.37 - $25.34 $196,055 - $286,012
11,287 Added 50.19%
33,774 $597,000
Q1 2021

May 06, 2021

BUY
$23.67 - $36.85 $11,716 - $18,240
495 Added 2.25%
22,487 $551,000
Q4 2020

Feb 10, 2021

BUY
$20.32 - $39.8 $270,418 - $529,658
13,308 Added 153.25%
21,992 $744,000
Q3 2020

Nov 12, 2020

SELL
$19.5 - $31.26 $27,787 - $44,545
-1,425 Reduced 14.1%
8,684 $217,000
Q2 2020

Aug 13, 2020

BUY
$25.68 - $38.12 $259,599 - $385,355
10,109 New
10,109 $341,000

Others Institutions Holding ORIC

About Oric Pharmaceuticals, Inc.


  • Ticker ORIC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,576,700
  • Market Cap $421M
  • Description
  • ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment r...
More about ORIC
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.